BioDefense Therapeutics reports successful Phase II trial of T-705a drug against influenza
The Phase II clinical trials were double blind and placebo-controlled with twice daily doses of T-705a. Those who received the drug experienced a significant decrease in the time taken to alleviate the six symptoms of an influenza infection and overcame illness faster than those who received a placebo.
The T-705a drug appears safe and well-tolerated, with no incidents of adverse effects. The U.S. Food and Drug Administration approved the drug for Phase III clinical trials, to be carried out by MediVector.
"We are encouraged by this important achievement; it means BD Tx is one step closer to providing the military and our nation with safe therapeutics to counter biological threats," Product Manager for BD Tx and U.S. Army Lieutenant Colonel Eric G. Midboe said. "The rapidly evolving viral flu strains, especially the emergence of drug resistant strains, make a broad-spectrum drug solution essential in any strategy to combat this and similar biological threats."
Influenza has a risk assessment of potentially infecting approximately 10 percent of the military population on a monthly basis. The T-705a drug was developed with this in mind and seeks to protect military personnel from multiple influenza strains, including H1N1 seasonal and pandemic strains, H5N1, H7N9 and drug-resistant influenza strains.
"We are concerned with not only naturally occurring flu strains, but also those that may be biologically engineered," Assistant Product Manager for BD Tx Dr. Tyler Bennett said. "T-705a has a unique mechanism of action that works by blocking viral RNA replication within the infected cell, giving T-705a the potential to be broad-spectrum. We intend to further test T-705a's efficacy against other viruses of interest to the DoD."